Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/appi.ajp.2011.11111622 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of the Effectiveness of Different Antidepressants in Preventing Psychiatric Rehospitalization.
Cureus
December 2024
Ernest Mario School of Pharmacy, Rutgers University, Piscataway, USA.
Objective: Patients with major depressive disorder (MDD) often face poor health outcomes. Additionally, patients with multiple hospitalizations tend to have worse predicted disease prognosis. Antidepressant medications remain a first-line treatment option for MDD, but data evaluating the effects of different antidepressants on psychiatric readmission rates is lacking.
View Article and Find Full Text PDFSertraline in depressed patients with or at risk for coronary heart disese: a systemic review.
Am J Cardiovasc Dis
December 2024
Otorhinolaryngology Research Center, Department of Otolaryngology and Head and Neck Surgery, School of Medicine, Amiralmomenin Hospital, Guilan University of Medical Sciences Rasht, Iran.
Background And Aims: Depression is a prevalent comorbidity among patients with coronary heart disease (CHD). While recent studies have hinted at a possible association between CHD and antidepressant medications like sertraline, the existing evidence remains inconclusive. To investigate this potential link, we conducted a comprehensive systematic review.
View Article and Find Full Text PDFDeveloping a translational research framework for MDD: combining biomolecular mechanisms with a spiraling risk factor model.
Front Psychiatry
January 2025
Department of Pharmaceutical Sciences and Freudenthal Institute, Utrecht University, Utrecht, Netherlands.
Objective: The global incidence and burden of Major Depressive Disorder (MDD) are increasing annually, with current antidepressant treatments proving ineffective for 30-40% of patients. Biomolecular mechanisms within the microbiota-gut-brain axis (MGBA) may significantly contribute to MDD, potentially paving the way for novel treatment approaches. However, integrating the MGBA with the psychological and environmental aspects of MDD remains challenging.
View Article and Find Full Text PDFData-driven discovery of associations between prescribed drugs and dementia risk: A systematic review.
Alzheimers Dement (N Y)
January 2025
Department of Health and Community Sciences, Medical School University of Exeter Exeter UK.
Abstract: Recent clinical trials on slowing dementia progression have led to renewed focus on finding safer, more effective treatments. One approach to identify plausible candidates is to assess whether existing medications for other conditions may affect dementia risk. We conducted a systematic review to identify studies adopting a data-driven approach to investigate the association between a wide range of prescribed medications and dementia risk.
View Article and Find Full Text PDFMicroglial-Biomimetic Memantine-Loaded Polydopamine Nanomedicines for Alleviating Depression.
Adv Mater
January 2025
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610064, China.
Depression is a common psychiatric disorder, and monoamine-based antidepressants as first-line therapy remain ineffective in some patients. The synergistic modulation of neuroinflammation and neuroplasticity could be a major strategy for treating depression. In this study, an inflammation-targeted microglial biomimetic system, PDA-Mem@M, is reported for treating depression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!